Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.15 CAD | +2.45% | +11.37% | +79.73% |
Apr. 19 | Canopy Growth Slides After Constellation Directors Leave, Share Conversion | DJ |
Apr. 18 | Stocks to Watch : Canopy Growth, Metropolitan Bank, Netflix | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's enterprise value to sales, at 4.07 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+79.73% | 656M | C- | ||
+35.04% | 5.92B | B- | ||
-15.13% | 4.51B | C+ | ||
-9.75% | 3.15B | B- | ||
+2.14% | 3.1B | C | ||
-6.82% | 2.42B | - | D+ | |
+47.87% | 1.97B | - | ||
-7.89% | 1.68B | - | - | |
+0.09% | 1.65B | - | - | |
-12.97% | 1.53B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WEED Stock
- Ratings Canopy Growth Corporation